Abstract
Introduction: Adipocytokines have been proposed as new mediators of the protective effects of fat mass on the skeleton. The aim of this study was to test the relationship between adiponectin, leptin, and bone mineral density (BMD), independently of body composition, insulin resistance, and other factors known to affect bone metabolism. Methods: Thirty-six post-menopausal non-diabetic elderly women, with ages ranging from 66 to 77 yr took part in the study. In all subjects we evaluated body weight, height, body mass index (BMI), waist circumference, adiponectin, leptin, insulin, DHEAS, and homeostasis model assessment of insulin resistance (HOMA), as well as yr since menopause. Total body fat mass (FM) and BMD at whole body and femoral level were measured with Dual energy X-ray Absorptiometry (DXA). Volumetric BMD was defined as the ratio between total body BMD and height. Results: Leptin was positively and adiponectin negatively related with whole body and femoral BMD. Positive associations between insulin, HOMA, DHEAS, and BMD measures were also found. After adjusting for FM, only adiponectin maintained a significant relation with whole body and femoral BMD; the strength of this association was reduced after adjustment for insulin resistance, estimated by HOMA. In stepwise multiple linear regression analyses adiponectin explained 11.7% of total BMD variance, 17.4% of femoral neck BMD variance, and 30.7% of volumetric BMD variance, independently of BMI, FM, leptin, HOMA, and DHEAS. Conclusions: The present study may suggest possible involvement of adiponectin in bone metabolism, independently of FM and insulin resistance even in elderly post-menopausal women.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Reid IR, Ames R, Evans MC, et al. Determinants of total body and regional bone mineral density in normal postmenopausal women-a key role for fat mass. J Clin Endocrinol Metab 1992, 75: 45–51.
Thomas T, Burguera B. Is leptin the link between fat and bone mass? J Bone Miner Res 2002, 17: 1563–9.
Berner HS, Lyngstadaas SP, Spahr A, et al. Adiponectin and its receptors are expressed in bone forming cells. Bone 2004, 35: 842–9.
Oshima K, Nampei A, Matsuda M, et al. Adiponectin increases bone mass by suppressing osteoclast and activating osteoblast. Biochem Biophys Res Commun 2005, 331: 520–6.
Luo XH, Guo LJ, Yuan LQ et al. Adiponectin stimulates human osteoblasts proliferation and differentiation via the MAPK signaling pathway. Exp Cell Res 2005, 309: 99–109.
Shinoda Y, Yamaguchi M, Ogata N, et al. Regulation of bone formation by adiponectin through autocrine/paracrine and endocrine pathways. J Cell Biochem 2006, 99: 196–208.
Díez JJ, Iglesias P. The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol 2003, 148: 293–300.
Luo XH, Guo LJ, Xie H, et al. Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway. J Bone Miner Res 2006, 21: 1648–56.
Lenchik L, Register TC, Hsu FC, et al. Adiponectin as a novel determinant of bone mineral density and visceral fat. Bone 2003, 33: 646–51.
Jürimäe J, Jürimäe T. Adiponectin is a predictor of bone mineral density in middle-aged premenopausal women. Osteoporos Int 2007, 18: 1253–9.
Jürimäe J, Rembel K, Jürimäe T, Rehand M. Adiponectin is associated with bone mineral density in perimenopausal women. Horm Metab Res 2005, 37: 297–302.
Richards JB, Valdes AM, Burling K, Perks UC, Spector TD. Serum adiponectin and bone mineral density in women. J Clin Endocrinol Metab 2007, 92: 1517–23.
Huang KC, Cheng WC, Yen RF, Tsai KS, Tai TY, Yang WS. Lack of independent relationship between plasma adiponectin, leptin levels and bone mineral density in nondiabetic female adolescents. Clin Endocrinol 2004, 61: 204–8.
Kontogianni MD, Dafni UG, Routsias JG, Skopouli FN. Blood leptin and adiponectin as possible mediators of the relation between fat mass and BMD in perimenopausal women. J Bone Miner Res 2004, 19: 546–51.
Oh KW, Lee WY, Rhee EJ, et al. The relationship between serum resistin, leptin, adiponectin, ghrelin levels and bone mineral density in middle-aged men. Clin Endocrinol (Oxf) 2005, 63: 131–8.
Thomas T. The complex effect of leptin on bone metabolism through multiple pathways. Curr Opin Pharmacol 2004, 4: 295–300.
Khosla S. Leptin central or peripheral to the regulation of bone metabolism? Endocrinology 2002, 143: 4161–4.
Ducy P, Amling M, Takeda S, et al. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 2000, 100: 197–207.
Zoico E, Zamboni M, Di Francesco V, Mazzali G, Fantin F, Bosello O. Leptin physiology and pathophysiology in the elderly. Adv Clin Chem 2006; 41: 123–66.
Zoico E, Zamboni M, Adami S et al. Relationship between leptin levels and bone mineral density in the elderly. Clin Endocrinol (Oxf) 2003, 59: 97–103.
Mazess RB, Barden HS, Bisek JP, Hanson J. Dual-energy X-ray Absorptiometry for total-body and regional bone-mineral and soft-tissue composition. Am J Clin Nutr 1990, 51: 1106–12.
Bonora E, Targher G, Alberiche M, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000, 23: 57–63.
Giagulli VA, De Pergola G, Giorgino F, et al. Increased free testosterone but normal 5 alpha-reduced testosterone metabolites in obese premenopusal women. Clin Endocrinol 1992, 36: 553–8.
SPSS-X User’s Guide, 2nd ed. New York: McGraw-Hill, 1986.
NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001, 285: 785–95.
Jürimäe J, Jürimäe T. Plasma adiponectin concentration in healthy pre- and postmenopausal women: relationship with body composition, bone mineral and metabolic variables. Am J Physiol Endocrinol Metab 2007, 293: E42–7.
Tankó LB, Christiansen C. Can confounding with fat-derived endogenous free estradiol explain the inverse correlation of bone mineral density with adiponectin? Bone 2004, 34: 916.
Cormier C, Souberbielle JC, Kahan A. DHEA in bone and joint diseases. Joint Bone Spine 2001, 68: 588–94.
Villareal DT. Effects of dehydroepiandrosterone on bone mineral density: what implications for therapy? Treat Endocrinol 2002, 1: 349–57.
Pei L, Tontonoz P. Fat’s loss is bone’s gain. J Clin Invest 2004, 113: 805–6.
Kahn E, Abu-Amer Y. Activation of perixosome proliferator activated receptor-γ inhibits differentiation of preosteoblasts. J Lab Clin Med 2003, 142: 29–34.
Ettinger MP. Aging bone and osteoporosis: strategies for preventing fractures in the elderly. Arch Int Med 2003, 163: 2237–46.
Cauley JA, Gutai JP, Kuller LH, LeDonne D, Powell JG. The epidemiology of serum sex hormones in postmenopausal women. Am J Epidemiol 1989, 129: 1120–31.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zoico, E., Zamboni, M., Di Francesco, V. et al. Relation between adiponectin and bone mineral density in elderly post-menopausal women: Role of body composition, leptin, insulin resistance, and dehydroepiandrosterone sulfate. J Endocrinol Invest 31, 297–302 (2008). https://doi.org/10.1007/BF03346361
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03346361